Background: Fatigue is a common problem in multiple sclerosis (MS) affecting as many as 90% of patients. The Fatigue Impact Scale (FIS) is a validated measure of fatigue in MS patients. The cause of fatigue in MS is likely multifactorial, with some evidence that ongoing central nervous system (CNS) inflammation is a contributing factor. Immunoablation and autologous hematopoietic stem cell transplantation (aHSCT) have been shown to halt ongoing CNS inflammation. Objective: To investigate whether halting all ongoing inflammation with aHSCT impacts FIS scores in patients with severe MS. Methods: In the Canadian aHSCT study (ClinicalTrials.gov, NCT01099930), 23 patients underwent aHSCT and had FIS prospectively collected every 6 months for 36 months of follow-up. Change in FIS was analysed by repeated-measures analysis of variance (RMANOVA) with multiple linear regression to determine independent predictors. Results: The median FIS score decreased 36%, from 36 to 23 (p = 0.001), and four patients had 100% reduction. Improvement in FIS correlated with lower age and Expanded Disability Status Scale at baseline, as well as increased independence as evidenced by a return to gainful employment and even driving. Conclusion: Patients had significantly less fatigue on average after aHSCT. This may serve to better understand the contribution of ongoing CNS inflammation to fatigue peculiar to MS.
Introduction
Up to 90% of patients with multiple sclerosis (MS) report fatigue, with over 50% reporting it as a one of their worst symptoms. 1 The pathophysiology for fatigue in MS is multifactorial: inflammation and disruption in the central nervous system (CNS) circuitry from the disease process contribute to primary MS fatigue, and secondary fatigue from muscle weakness, depression and increased effort in daily activities due to disability also plays a role. [2] [3] [4] In addition to understanding the cause of fatigue in MS, accurate measurement is required to guide treatment. However, fatigue is subjective and varies over the course of the disease, which makes its measurement challenging.
The Fatigue Impact Scale (FIS) was introduced in 1994 by Fisk et al. 1 The FIS is a 40-question Likert-type scale tool, where patients grade how fatigue impacts their wellbeing. Scores range from 0-160, with higher scores indicating greater impact from fatigue. Questions fall into three subcategories of fatigue: cognitive, physical and social (Supplementary Data S1). An abridged 21-question modified Fatigue Impact Scale (mFIS) was developed by the Multiple Sclerosis Quality-of-Life Inventory panel to be less redundant. The mFIS has been validated in several countries to correlate fatigue with disability and quality of life. 5, 6 Furthermore, the mFIS is recommended by the Multiple Sclerosis Council for Clinical Practice Guidelines for use in monitoring MS fatigue. 7 Despite this, the practical use of the mFIS has been a topic of debate. Some evidence shows that an absolute score over 38 can delineate bothersome fatigue, while other cohorts do not replicate this; regardless, a decrease in mFIS over time correlates with reducing the impact of fatigue on an individual patient's wellbeing and thus can be a marker of treatment response with respect to fatigue. 8, 9 Treatments targeting MS fatigue have had mixed success. Some goals of fatigue therapy are to address comorbidities that might contribute to secondary fatigue such as depression, pain, sleep disturbance or spasticity and to stimulate mental alertness through various pharmacologic mechanisms. [10] [11] [12] There is also evidence that the disease modification through immune suppression improves fatigue. 13, 14 We have shown that immunoablation followed by rescue with autologous hematopoietic stem cell transplantation (aHSCT) completely halts all detectable CNS inflammatory activity in patients with aggressive forms of MS. 15 This procedure exacerbates fatigue in patients with leukaemia, with data pointing to the regimen as a cause. 16 However, this has not been studied in patients receiving aHSCT for MS, who may experience fatigue for inflammatory reasons.
In this paper, we analysed the same set of patients from the Canadian aHSCT study 15 before and after treatment to investigate whether aHSCT had an effect on patient-described fatigue, using the change in FIS over time.
Methods

Study, patients and intervention
This prospective study reports new data on the previously reported Canadian aHSCT patients (ClinicalTrials.gov, NCT01099930). 15, 17 Briefly, patients with MS who had ongoing relapses and progression despite disease-modifying therapy were treated with immunoablative conditioning regimens followed by rescue with autologous hematopoietic stem cells that were previously mobilized. The conditioning regimen consisted of a 9-day course of busulfan and cyclophosphamide followed by rabbit anti-thymocyte globulin, and the stem cells were purified using CD34+ immunomagnetic selection and frozen. 18 Patients were seen in the frequent follow-up, as well as every 6 months, to complete the self-reported 40-item FIS questionnaire up to 3 years after aHSCT, totalling seven measurements per patient. Research staff and independent investigators, not the treating neurologist, supervised all fatigue assessments in clinic visits.
The study was approved by the research ethics board and monitored by an independent data and safety monitoring committee. Patient information and assessments were kept in a locked area and data were anonymous and analysed on encrypted devices.
Outcome variables
The primary outcome variable studied was the change in the mFIS. The secondary outcomes included change in the subcategories of the FIS and change in the global FIS. Patient demographics, previous treatments for fatigue and depression, baseline Expanded Disability Status Scale (EDSS) and sustained progression of disability, which was defined as worsening of EDSS by at least 1 point from baseline, as well as the patient's subjective impression of fatigue, were investigated for the association with change in FIS scores. In addition, changes in social wellbeing such as employment or driving status, as well as being in a relationship, were analysed for association with change in FIS scores. Both the absolute FIS score and a change in FIS were investigated for significant impact on social wellbeing markers.
Statistical analysis
All patients received aHSCT and had the same predefined time points when the FIS was to be repeated, and therefore the primary analysis of change in FIS scores was performed using a repeated-measures analysis of variance (RMANOVA) reporting significance (p < 0.05). Missing FIS data points were considered to be random and thus handled by multiple imputation procedure. Patients who did not complete follow-up had their final measured FIS score treated as the end-of-trial score (the last observation carried forward). Variables reaching a statistical trend in univariate analysis (p < 0.10) by Mann-Whitney U-test, Wilcoxon signed-rank test or Fisher's exact test, as appropriate, were included in a stepwise forward inclusion multiple linear regression analysis to determine independent predictors of change in FIS. A Bonferroni correction method was applied for multiple comparisons, such that a p-value of less than 0.01 was deemed statistically significant. All statistical analyses were performed using SPSS (IBM Statistics, version 24).
Results
There were 148 FIS measurements performed prospectively in 23 patients over a follow-up of 69 patient-years. Two patients had follow-up censored at 14 and 23 months after dropping out of the study and undergoing a procedure for the treatment of the controversial chronic cerebrospinal venous insufficiency condition after they had sustained progression of disability. There were seven missed appointments, which were due to patients being out of the city on four occurrences, having no ride to appointment for two occurrences and one undefined. Patient characteristics at baseline compared to the end of the follow-up period are shown in Table 1 .
At baseline, 20 patients (87%) endorsed fatigue and the median mFIS score (interquartile range (IQR)) was 36 (30-46.5) . At the first follow-up, 6 months after aHSCT, the median mFIS already decreased to 25.5 (15.5-40.5), and this reduction was sustained until the end of the trial with an mFIS of 23 (9-41.5) and a 36% reduction overall (RMANOVA; p = 0.001, 95% confidence interval (CI): 11%-53%). Each subcategory score of FIS was also statistically significantly less at the end of the trial (Figure 1 ). Individual patient FIS scores at each time point are also reported (Supplementary Data S2) along with their overall change in mFIS ( Figure 2 ). The seven patients (30%) who had sustained progression of disability had a median baseline mFIS score of 41, which reduced 12.9% after aHSCT, while the 16 without progression (70%) had a baseline mFIS of 36, which improved by 35.8% after treatment (p = 0.029).
Univariate, pairwise comparisons of predictors for greater change in mFIS scores are shown in Table 2 , with subcategory FIS scores also being reported (Supplementary Data S3). There was an association for higher age and EDSS at aHSCT with less reduction in mFIS, which was strongly associated in multivariate analysis as shown in Table 3 . Importantly, at no point was age associated with worsening fatigue after aHSCT in our cohort. There was a trend towards a greater reduction in cognitive FIS subcategory score for females, non-smokers, those without sustained progression of disability and those with lower baseline EDSS; however, on multivariate analysis, baseline EDSS remained strongly associated with change in cognitive FIS and patients who had no sustained progression of disability had significantly less cognitive FIS scores. For physical FIS score, there was a trend for lower age at aHSCT to a greater reduction, while lower EDSS at aHSCT was statistically significant. And for global FIS lower age at aHSCT and baseline EDSS both trended to lower scores. Although these two variables were also trending towards a reduction in social FIS, neither was statistically significant on multivariate analysis.
There were also some interesting trends observed in terms of concurrent treatment of depression and fatigue. There were eight (35%) patients on antidepressant medications with a baseline mFIS of 42.5 who had a 14% reduction, compared to 15 patients (65%) not on antidepressants with a baseline mFIS of 35 who had a 35% reduction (p = 0.08). There were no effects of anti-fatigue medication on mFIS change: eight patients (35%) took anti-fatigue medications at baseline (four on amantadine and four on modafinil) with a baseline mFIS of 44 who had a 31% reduction compared to 15 patients (65%) not on fatigue medications with a baseline mFIS of 35 who had a 24% reduction (p = 0.74). All patients on anti-fatigue medications rated their fatigue as 'affecting activities'; however, six patients not on anti-fatigue medications (37.5%) had fatigue 'affecting activities' as well. No anti-fatigue medications were started or discontinued over the course of the study.
At the end of the study period, there were four patients (17%) who had a 100% improvement in their FIS and 15 patients (65%) who had an absolute mFIS less than 38, 13 of which (87%) had over 25% reduction in their mFIS scores. There was no significant difference in social wellbeing outcomes between patients who had mFIS less than 38 compared to those with over 25% reduction in mFIS score; however, either of the groups had overall more wellbeing markers and was less likely to endorse fatigue (Table  4) . Notably, at baseline four (17%) patients were employed, only one of which had a baseline mFIS over 38. After aHSCT, at the end of the trial, seven patients came off disability and gained employment, which was associated with a lower median mFIS score of 16 compared to those who were unemployed at the end of the trial who had a median mFIS of 32 (p = 0.023). One patient who was working at baseline had sustained progression, was on disability at the end of the trial and had an increase in FIS scores in all subcategories. The eight (33%) patients driving at baseline did not have significantly different FIS scores from non-drivers (45 vs 35, p = 0.075); however, at the end of the trial, driving was associated with lower total mFIS scores (19 vs 76, p = 0.048). After aHSCT, four patients gained valid driver's licences and one patient no longer had his/her. Over the 3-year follow-up period after aHSCT, five patients either got married or entered common-law relationships, and two patients had children with banked or donated gametes, though there was no significant difference in mFIS scores among these groups.
Discussion
This study demonstrates that aHSCT in aggressive MS reduced the overall subjective reporting of fatigue, as well as numeric FIS scores, in 18 of the 23 patients (78%) enrolled in the Canadian aHSCT study. Compared to other cohorts, our patients had similar baseline mFIS scores despite the severe disease and failing previous disease-modifying therapies. 8 The mFIS score seemed to reliably correlate with subjective fatigue; additionally, an absolute score less than 38, or a reduction in fatigue score greater than 25%, seemed to correlate with better social outcomes. Interestingly, although the baseline FIS score did not predict change in fatigue after aHSCT, patients, on average, had reduced fatigue scores after cessation of immune activity; thus, inflammation likely plays a key role in MS fatigue.
The use of aHSCT in patients with aggressive MS has been shown to halt all ongoing detectable CNS Table 2 and Supplementary Table S3 .
inflammatory activity with the potential to drastically change the disease course. This study shows that aHSCT may also improve quality of life and social wellbeing by means of improving fatigue. However, the high-dose immunoablative regimen and intensive graft selection used in this protocol differ from other hematopoietic stem cell therapies for MS, so fatigue score outcomes cannot be generalized. [19] [20] [21] [22] [23] Despite the absence of clinical or radiological hallmarks of disease-related CNS inflammation in this patient group, seven (30%) patients did sustain disability progression by means of worsening EDSS. 15 In these patients, the cognitive FIS subcategory actually worsened to a significant degree (-46% vs 35%, p = 0.005); however, the overall mFIS scores did not significantly differ from those with stable EDSS. This may indicate that the cognitive impact of fatigue is associated with worsening EDSS, as opposed to physical disability alone, as previously suggested. 2 Regardless, higher baseline EDSS was associated with lower improvement of mFIS, as was older age at the time of aHSCT, which is similar to the subpopulation that has less benefit from aHSCT in other clinical spheres. 24 The overall improvement of FIS in patients in this study supports the hypothesis that active inflammation is an important, potentially remediable, contributor to MS fatigue. This concept is supported by previous studies showing reduced fatigue after immunosuppressive treatment. 14, [25] [26] [27] [28] This was demonstrated in the ENER-G reporting mFIS after treatment with natalizumab, which showed a reduction in mean (standard deviation (SD)) mFIS from a baseline score of 59.1 (12.2) to 51.6 (16.3) after 12 weeks. 14 This was previously the most robust change in mFIS in the immunosuppressive literature and was shown to have a durable response for up to 48 weeks. However, the longer-term effect of the medication on fatigue is less clear, there was no control group and the overall FIS scores were still quite high. Our study had a younger patient population with shorter disease duration, which may account for lower baseline mFIS compared with the ENER-G cohort. Thus, in addition to more intensive immune suppression by aHSCT, the different cohort in our study may explain, in part, why our cohort had such significant improvement in fatigue after treatment.
Treatments for MS fatigue are multidimensional as fatigue is multifactorial. 29 Non-pharmacologic treatments such as regular sleep, exercise and cognitive behavioural therapy are important, as well as treatment of comorbidities such as depression, sleep disturbances from apnoea, nocturnal myoclonus, restless legs syndrome, muscle spasms and thyroid dysfunction. In our study, patients with a diagnosis of depression had less improvement in mFIS and physical FIS subcategory regardless of baseline EDSS, suggesting that depression can exacerbate fatigue, regardless of disability, as had been previously described. 2, 4, 9 Other treatments for MS fatigue involve pharmacologic agents, which act through various mechanisms including in hypothalamic pathways such as modafinil, or as dopaminergic drugs such as pemoline, methylphenidate or amantadine. 3, 12 These treatments have had mixed results showing benefit in some cases, a metaanalysis exhibiting a trend towards amantadine being effective; however, small sample sizes and placebo effects in fatigue remain common confounders. 12, 30, 31 In our study, the patients on anti-fatigue medications remained on them, though none was initiated during the course of the follow-up. There was no difference in change in FIS scores for patients on anti-fatigue medications compared to those who are not, but both groups had improvement in their fatigue, which may indicate that the underlying mechanism of fatigue in MS is not fully targeted by current anti-fatigue treatments.
The major limitations of our study were the small sample size, lack of an adequate placebo or control group and the fact that the primary outcome was a composite of multiple measurements using the mFIS. Although there were only 23 patients, there were 148 total measurements in the 3-year study period, which allowed for statistical analysis, but wider CIs were noted with any attempt at subset analyses, such as in those taking antidepressants. There was no comparative control group to assess for the placebo or learning effect of repeated FIS administrations, which are well known concerns with questionnaire-based outcomes; however, given the severity of MS in the young patients of this cohort and potential for improvement with aHSCT, it was not possible to assign one in this multi-centre study. These factors limit conclusions as to which patients may benefit more from aHSCT from the fatigue perspective by multivariate analysis, but younger patients with less disability seemed to improve more. It is reassuring, however, that patients who had a positive change in social wellbeing also had a greater reduction in mFIS scores, especially those who were employed or maintained a driver's licence at the end of the study period, irrespective of mFIS at baseline.
The improvements in mFIS we observed as early as 6 months following intense immunoablative stem cell transplantation procedure may have been unexpected and are particularly interesting. Previous studies have shown that this treatment increased fatigue in patients with hematologic malignancy. 16, 32, 33 In those studies, however, the fatigue assessments were not performed using the FIS, patients were older and many were palliative with presumably functional impairment. In comparison, our patients had reduced fatigue after aHSCT; thus, MS fatigue may well be pathophysiologically different than that suffered by cancer patients, and the potent anti-inflammatory effects of aHSCT alleviate fatigue in MS patients. 34 The improvement in fatigue observed in some, but not all, of our patients with severe MS in whom all detectable CNS inflammation was eliminated by aHSCT helps understand that ongoing inflammation is but one key component of MS primary fatigue. The majority of improvement was seen within the first 6 months, at a time when the treatment itself would impact most non-MS patients by producing fatigue. Thus, this suggests that abrogation of MS-related inflammation outweighed the tendency of the conditioning drugs to produce fatigue and the net result was improvement. It was therefore not surprising that early improvements in fatigue were shown to be sustained for up to 3 years.
There are many more patients undergoing various forms of aHSCT currently as a result of the success of smaller intense studies, such as ours. Assessing the impact of these treatments on MS fatigue would help further verify our results.
